
CLYM Stock Forecast & Price Target
CLYM Analyst Ratings
Bulls say
Climb Bio Inc. has raised its peak worldwide patient estimates for its therapeutic candidate budoprutug to 15,500, indicating a significant market opportunity and corresponding peak sales potential of $1.8 billion due to the lack of competition in CD19-targeted treatments for pMN. The company's recent acquisition of Tenet Medicines, along with a $120 million private investment in public equity (PIPE), has notably enhanced its valuation, positioning Climb Bio favorably for future growth. Additionally, positive clinical data from both budoprutug and CLYM116 may drive substantial equity value appreciation, paralleling the value inflection seen with similar companies in the biotechnology sector.
Bears say
Climb Bio Inc has never achieved profitability, which raises concerns regarding its financial sustainability and ability to fund ongoing and future clinical trials. Additionally, there are significant risks associated with the advancement of its product candidates, specifically budoprutug and CLYM116, which may face challenges in clinical development and securing regulatory approvals. The company is also exposed to partnership risks and potential dilution, further complicating its financial outlook amidst the backdrop of underperforming competitors and clinical trials with uncertain outcomes.
This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
CLYM Analyst Forecast & Price Prediction
Start investing in CLYM
Order type
Buy in
Order amount
Est. shares
0 shares